Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 55.1%

Atyr PHARMA INC (NASDAQ:ATYR) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,660,000 shares, a growth of 55.1% from the October 15th total of 1,070,000 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average trading volume of 761,100 shares, the short-interest ratio is presently 2.2 days.

Analyst Ratings Changes

Several research analysts have recently weighed in on ATYR shares. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, October 29th. Royal Bank of Canada restated an “outperform” rating and set a $16.00 target price on shares of Atyr PHARMA in a report on Wednesday, August 14th. Wells Fargo & Company initiated coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective for the company.

Atyr PHARMA Price Performance

NASDAQ:ATYR traded down $0.29 during trading hours on Friday, hitting $2.91. The company’s stock had a trading volume of 1,386,422 shares, compared to its average volume of 574,810. The stock has a market capitalization of $243.85 million, a P/E ratio of -3.10 and a beta of 1.10. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a twelve month low of $1.09 and a twelve month high of $3.80. The stock has a fifty day simple moving average of $2.47.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, equities analysts predict that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.